10-K: Cencora, Inc. Reports Fiscal Year 2024 Results, Announces Acquisition of Retina Consultants of America

Cencora, Inc. reports a 12.1% increase in revenue for fiscal year 2024, driven by growth in U.S. Healthcare Solutions, and announces the acquisition of Retina Consultants of America for approximately $4.6 billion.

Summary

• Cencora, Inc. reported a 12.1% increase in revenue for fiscal year 2024, reaching $293.96 billion, primarily driven by a 13% growth in the U.S. Healthcare Solutions segment.
• The U.S. Healthcare Solutions segment saw significant growth due to increased sales of GLP-1 products, specialty pharmaceuticals, and COVID-19 therapies and vaccines.
• International Healthcare Solutions revenue increased by 4.4%, driven by growth in European distribution and Canadian businesses.
• Gross profit increased by 10.6% to $9.91 billion, influenced by higher sales and a LIFO credit, partially offset by lower gains from antitrust litigation settlements.
• Operating expenses increased by 16.9% due to a $418 million goodwill impairment related to PharmaLex and increases in distribution, selling, administrative, litigation, and amortization expenses.
• Total segment operating income increased by 10.9% to $3.65 billion, with U.S. Healthcare Solutions up 13% and International Healthcare Solutions up 3%.
• The effective tax rate was 24.2% in fiscal 2024, higher than the 19.8% in fiscal 2023, primarily due to the PharmaLex goodwill impairment.
• The company announced an agreement to acquire Retina Consultants of America for approximately $4.6 billion, with an expected cash outlay of $4.3 billion at closing and potential contingent consideration of up to $500 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue growth offset by increased expenses and a goodwill impairment. The acquisition of Retina Consultants of America is a positive development, but the potential loss of a key customer and ongoing opioid litigation create uncertainty. Overall, the sentiment is cautiously optimistic.

Positives

• Revenue growth was strong, with a 12.1% increase year-over-year.
• The U.S. Healthcare Solutions segment showed significant growth, driven by key product categories.
• Gross profit increased by 10.6%, indicating improved profitability.
• The company secured a new pharmaceutical supply agreement with Evernorth Health Services for an additional three years.
• The company has a robust distribution facility network in the United States.
• The company has a strong focus on talent development and diversity, equity, and inclusion initiatives.

Negatives

• Operating expenses increased significantly by 16.9%, driven by a goodwill impairment and higher operating costs.
• The effective tax rate increased to 24.2% due to the PharmaLex goodwill impairment.
• The company anticipates a potential loss of an oncology customer in June 2025 due to a pending acquisition.
• The company experienced a cybersecurity event in March 2024, incurring related costs.
• The company is subject to ongoing opioid-related legal proceedings and the Distributor Settlement Agreement, which could impact cash flows.

Risks

• The loss of a key customer or group purchasing organization could adversely affect revenue and results of operations.
• The anticipated benefits of the relationship with Walgreens Boots Alliance may not be fully realized.
• Acquisitions and investments may not perform as expected or be difficult to integrate.
• Geopolitical and other risks associated with international operations could materially impact financial results.
• Fluctuations in foreign currency exchange rates could adversely affect financial results.
• The company is subject to operational and logistical risks that might not be covered by insurance.
• Increasing governmental efforts to regulate the pharmaceutical supply chain may increase costs and reduce profitability.
• Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect business and results of operations.
• Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect the business.
• Tax legislation or challenges to tax positions could adversely affect results of operations and financial position.
• Violations of anti-bribery, anti-corruption, and/or international trade laws could have a material adverse effect on the business.
• Failure to adequately protect personal data could result in claims of liability and damage the company's reputation.
• Third-party business partners are vulnerable to cybersecurity risks, and any cyber incident affecting them could significantly disrupt operations.
• Failure to protect the company's reputation could have a material adverse effect on business and operations.
• Intellectual property rights may not provide meaningful commercial protection for services, solutions, or brands.
• The company is adversely impacted by events outside of its control, such as widespread public health issues, natural disasters, government policy changes, and political events.
• Goodwill or long-lived assets may become impaired, which may require the company to record a significant charge to earnings.

Future Outlook

The company expects to continue to grow revenue and increase operating income through the execution of its business strategy, including optimizing and growing its U.S. and international healthcare solutions businesses, and through acquisitions and investments. The company expects to spend approximately $600 million for capital expenditures during fiscal 2025.

Management Comments

• The company is focused on driving executional excellence in its core distribution solutions business.
• The company is investing in higher-margin, high-growth adjacencies to support the clinical development and commercialization of therapies.
• The company is well positioned to grow revenue and increase operating income through the execution of its business strategy.

Industry Context

The pharmaceutical industry is expected to grow at a compound annual growth rate of approximately 8.2% from 2023 through 2028, driven by factors such as an aging population, the introduction of new pharmaceuticals, and increased use of generic and biosimilar drugs. Cencora is positioned to benefit from these trends through its distribution and value-added services.

Comparison to Industry Standards

• Cencora's largest competitors are McKesson Corporation and Cardinal Health, Inc.
• Cencora competes with national generic distributors, regional distributors, manufacturers who sell directly to customers, chain drugstores who manage their own warehousing, specialty distributors, and packaging and healthcare technology companies.
• Cencora believes it has one of the lowest operating cost structures among pharmaceutical distributors.
• Cencora's U.S. human health distribution businesses compete with both McKesson and Cardinal, as well as national generic distributors and regional distributors within pharmaceutical distribution.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation related to the distribution of prescription opioid medications.
• The company is subject to ongoing investigations by governmental and regulatory agencies regarding the manufacture, dispensing, and distribution of opioid and other controlled substance medications.
• The company is involved in a lawsuit filed by the Mayor and City Council of Baltimore, with a jury verdict finding the company liable for public nuisance.
• The company is involved in a class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors.
• The company is involved in a class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals.
• The company is subject to a civil Complaint filed by the Department of Justice alleging violations of the Controlled Substances Act.
• The company is involved in a civil antitrust complaint alleging a conspiracy to fix prices, allocate markets and rig bids regarding generic drugs.
• The company is subject to a criminal investigation into MWI Veterinary Supply Co. in connection with grand jury subpoenas relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products.

Related Party Transactions

• The company has various agreements and arrangements with Walgreens Boots Alliance, Inc. (WBA), a related party, including a pharmaceutical distribution agreement and a generic purchasing services arrangement.
• Revenue from agreements with WBA accounted for approximately 26% of the company's revenue in fiscal 2024.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, strategic decisions, and legal proceedings.
• Employees may be impacted by changes in the company's operations, workforce reductions, and talent development programs.
• Customers may be impacted by changes in the company's product offerings, pricing, and service levels.
• Suppliers may be impacted by changes in the company's purchasing policies and supply chain management.
• Creditors may be impacted by the company's debt levels and financial performance.

Next Steps

• The company will continue to integrate the operations of acquired businesses, including PharmaLex.
• The company will continue to invest in advanced information systems and automated warehouse technology.
• The company will continue to implement its strategic plan to optimize and grow its U.S. and international healthcare solutions businesses.
• The company will work to complete the acquisition of Retina Consultants of America.

Key Dates

Keywords

pharmaceutical distribution, healthcare solutions, specialty pharmaceuticals, generic pharmaceuticals, oncology, biotech, supply chain, acquisitions, international operations, regulatory compliance, opioid litigation, cybersecurity, financial results